InMed Pharmaceuticals Strengthens Patent Portfolio With Issuance of Three U.S. Patents
InMed Pharmaceuticals Strengthens Patent Portfolio With Issuance of Three U.S. Patents
- InMed's intellectual property portfolio totals 13 patent families covering new chemical entities, formulations, manufacturing methods and methods of use
- InMed的知识产权组合共计13个专利族,涵盖了新化学物质、配方、制造方法和使用方法
Vancouver, British Columbia--(Newsfile Corp. - August 21, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced it has been issued three U.S. patents: one for its formulation and method of use in the treatment of epidermolysis bullosa and related connective tissue disorders, one for biosynthesis manufacturing processes and one for an ocular drug delivery formulation.
温哥华,不列颠哥伦比亚--(Newsfile corp. - 2024年8月21日)-InMed药业股份有限公司(纳斯达克:INM)("InMed"或"公司"),一家专注于开发一系列为存在高度未满足医疗需求的疾病提供专有小分子药物候选品管道的制药公司,今天宣布已获得了三项美国专利:一项用于治疗表皮水疱和相关结缔组织疾病的配方和使用方法的专利,一项生物合成制造工艺的专利,以及一项眼药物递送配方的专利
The method of use patent, entitled "Use of topical formulations of cannabinoids in the treatment of epidermolysis bullosa and related connective tissue disorders" relates to INM-755 drug candidate which has completed a Phase 2 clinical trial in the treatment of symptoms related to epidermolysis bullosa. The patent has now been granted in the U.S., Australia, Japan and Israel and is pending in several other jurisdictions. The biosynthesis patent for the manufacturing of proprietary analogs for our drug development programs has been granted in U.S. Additionally, an ocular drug delivery formulation and use patent has been granted/allowed in the U.S., Europe, Australia, Japan, and India and is also pending in other jurisdictions.
使用专利方法,标题为"在表皮水疱和相关结缔组织疾病治疗中使用大麻类局部制剂",涉及已完成第2期临床试验的INm-755药物候选品,用于治疗与表皮水疱相关的症状。 该专利目前已在美国、澳大利亚、日本和以色列获得批准,并在其他一些司法管辖区等待批准。生物合成专利用于生产用于我们药物开发项目的专有类似物已在美国获得批准。此外,眼药物递送配方和使用专利已在美国、欧洲、澳大利亚、日本和印度获得/获准,并在其他司法管辖区等待批准
As of August 20, 2024, InMed has a total of 13 patent families covering new chemical entities, formulations, manufacturing processes and methods of use. The Company continues to pursue new chemical entity patents on the drug candidates for both its INM-901 program in Alzheimer's disease and INM-089 in dry Age-related Macular Degeneration.
截至2024年8月20日,InMed拥有共计13个专利族,涵盖了新化学物质、配方、制造工艺和使用方法。 公司继续寻求关于其INm-901阿尔茨海默病和INm-089干性年龄相关性黄斑变性药物候选品的新化学物质专利
Summary of Granted Patents (to date):
已批准专利摘要(截至目前):
Subject Matter | Scope | Status and jurisdiction |
Use of topical formulations of cannabinoids in the treatment of epidermolysis bullosa and related connective tissue disorders | Method of Use |
Granted: US, Australia, Japan, Israel Pending: Several jurisdictions |
Metabolic engineering of E. coli for the biosynthesis of cannabinoid products | Manufacturing Process |
Granted: U.S. (will be issued on 9/3/24) Pending: Several jurisdictions |
Ocular drug delivery formulation | Formulation, Method of Use | Granted/Allowed: Australia, Japan, India, Europe, U.S. |
Recombinant production systems for prenylated polyketides of the cannabinoid family | Manufacturing Process |
Granted: U.S., Mexico Pending: Several jurisdictions |
主题 | 范围 | |
在治疗表皮松解性疱疹和相关结缔组织疾病中使用大麻素的局部制剂 | 使用方法 | 已获得的国家:美国、澳大利亚、日本、以色列 待定国家:其他国家和地区 |
大肠杆菌的代谢工程用于大麻素产品的生物合成 | 制造过程 | 已获得的国家:美国(将于9/3/24发布) 待定国家:其他国家和地区 |
眼部药物递送配方 | 配方,使用方法 | 已授权/批准:澳洲,日本,印度,欧洲,美国 |
用于大麻素家族表前多烯聚酮的重组生产系统 | 制造流程 | 已授予:美国,墨西哥 待定:多个司法管辖区 |
InMed's President and CEO, Eric A. Adams, said "We are pleased to announce these U.S. patent issuances which help increase the commercial value of our programs and ensure the long-term protection of our drug research and development efforts. We are committed to continuing to build our patent portfolio to protect our novel drug candidates, methods of manufacturing these drugs, how they are formulated and how they are used to support the development of new treatments for diseases with high unmet medical needs."
InMed的总裁兼首席执行官Eric A. Adams表示"我们很高兴宣布这些美国专利的颁发,这有助于增加我们项目的商业价值,并确保我们药物研究和开发工作的长远保护。我们致力于继续建立我们的专利组合,以保护我们的新型药物候选者,这些药物的制造方法,如何配制以及如何用于支持开发治疗存在高度未满足医疗需求疾病的新疗法。
About InMed:
关于InMed:
InMed Pharmaceuticals is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications. Together with our subsidiary BayMedica, we are a global leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary small molecule drug candidates. For more information, visit .
InMed Pharmaceuticals是一家制药公司,专注于开发针对CB1/CB2受体的专有小分子药物候选品管道。InMed的管道包括三个单独的计划,用于治疗阿尔茨海默病、眼科和皮肤学指示。与我们的子公司BayMedica一起,我们是罕见的大麻素和专有小分子药物候选品的制造、开发和商业化的全球领军者。欲了解更多信息,请访问。
Investor Contact:
投资者联系:
Colin Clancy
Vice President, Investor Relations
and Corporate Communications
T: +1 604 416 0999
E: IR@inmedpharma.com
Colin Clancy
投资者关系副总裁
和企业通讯
电话号码:+1 604 416 0999
电子邮件:IR@inmedpharma.com
Cautionary Note Regarding Forward-Looking Information:
有关前瞻性信息的警示:
This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "potential", "possible", "would" and similar expressions. Such statements, based as they are on current expectations of management, inherently involve numerous risks, uncertainties and assumptions, known and unknown, many of which are beyond our control. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Without limiting the foregoing, forward-looking information in this news release includes, but is not limited to, statements about: pursuing new chemical entity patents on the drug candidates for both its INM-901 program in Alzheimer's disease and INM-089 in dry Age-related Macular Degeneration; continuing to build a patent portfolio to protect of composition of matter, formulations, manufacturing processes and methods of use.
Additionally, there are known and unknown risk factors which could cause InMed's actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing InMed's stand-alone business is disclosed in InMed's Annual Report on Form 10-K and other filings with the Securities and Exchange Commission on www.sec.gov.
此外,已知和未知的风险因素可能会导致InMed的实际结果、表现或成就与这里所包含的前瞻性信息未来的结果、表现或成就存在实质性的差别。关于InMed的独立业务所面临的所有风险和不确定因素的完整讨论已在InMed的年报10-K表和其他提交给www.sec.gov的证券交易委员会的文件中披露。
All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.
此处所有的前瞻性信息都受到这一警示声明的限制,并且InMed放弃了对任何此类前瞻性信息进行修订和更新或公开宣布任何对此类前瞻性信息所做修订的结果来反映未来的结果、事件或发展的义务,除非法律要求其这样做。